These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 1381081)

  • 1. Direct current application: easy induction of ventricular fibrillation for the determination of the defibrillation threshold in patients with implantable cardioverter defibrillators.
    Weismüller P; Richter P; Binner L; Grossmann G; Hemmer W; Höher M; Kochs M; Hombach V
    Pacing Clin Electrophysiol; 1992 Aug; 15(8):1137-43. PubMed ID: 1381081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial clinical experience with endocardial defibrillation using an implantable cardioverter/defibrillator with a triple-electrode system.
    Saksena S; Tullo NG; Krol RB; Mauro AM
    Arch Intern Med; 1989 Oct; 149(10):2333-9. PubMed ID: 2802898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low energy cardioversion with the implantable cardioversion defibrillator devices for treatment of ventricular tachycardia and ventricular fibrillation].
    Siebels J; Schneider MA; Kuck KH
    Z Kardiol; 1993 Nov; 82(11):683-91. PubMed ID: 8291289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.
    Fromer M; Brachmann J; Block M; Siebels J; Hoffmann E; Almendral J; Ohm OJ; den Dulk K; Coumel P; Camm AJ
    Circulation; 1992 Aug; 86(2):363-74. PubMed ID: 1638705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The implantable automatic cardioverter-defibrillator].
    Klein H; Tröster J; Trappe HJ; Becht I; Siclari F
    Herz; 1990 Apr; 15(2):111-25. PubMed ID: 2188891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation.
    Khastgir T; Lattuca J; Aarons D; Murphy J; O'Mara V; Juanteguy J; Veltri EP
    Pacing Clin Electrophysiol; 1991 May; 14(5 Pt 1):768-72. PubMed ID: 1712951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical experience with a second-generation cardioverter-defibrillator].
    Meyer BJ; Candinas R; Gloor HO; Bertel O; Amann FW; Turina MI
    Schweiz Med Wochenschr; 1991 Nov; 121(46):1701-5. PubMed ID: 1957143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantation of additional defibrillation lead into the coronary sinus: an effective method of decreasing defibrillation threshold.
    Wilczek R; Swiątkowski M; Czepiel A; Sterliński M; Makowska E; Kułakowski P
    Kardiol Pol; 2011; 69(12):1308-9. PubMed ID: 22219117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A permanent transvenous lead system for an implantable pacemaker cardioverter-defibrillator. Nonthoracotomy approach to implantation.
    Yee R; Klein GJ; Leitch JW; Guiraudon GM; Guiraudon CM; Jones DL; Norris C
    Circulation; 1992 Jan; 85(1):196-204. PubMed ID: 1728450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators.
    Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS
    J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator.
    Guarnieri T; Levine JH; Veltri EP; Griffith LS; Watkins L; Juanteguy J; Mower MM; Mirowski M
    Am J Cardiol; 1987 Nov; 60(13):1061-4. PubMed ID: 3673907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of duration of ventricular fibrillation on defibrillation efficacy in humans.
    Winkle RA; Mead RH; Ruder MA; Smith NA; Buch WS; Gaudiani VA
    Circulation; 1990 May; 81(5):1477-81. PubMed ID: 2331763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized evaluation of effect of ventricular fibrillation duration on defibrillation thresholds in humans.
    Bardy GH; Ivey TD; Allen M; Johnson G
    J Am Coll Cardiol; 1989 May; 13(6):1362-6. PubMed ID: 2703617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of ventricular fibrillation duration and site of initiation on the defibrillation threshold during early ventricular fibrillation.
    Strobel JS; Kenknight BH; Rollins DL; Smith WM; Ideker RE
    J Am Coll Cardiol; 1998 Aug; 32(2):521-7. PubMed ID: 9708486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of ventricular fibrillation duration on defibrillation energy in dogs using bidirectional pulse discharges.
    Echt DS; Barbey JT; Black JN
    Pacing Clin Electrophysiol; 1988 Sep; 11(9):1315-23. PubMed ID: 2460837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.
    Skowasch D; Ringquist S; Nickenig G; Andrié R
    PLoS One; 2018; 13(3):e0194496. PubMed ID: 29566033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful implantation of cardioverter-defibrillator systems in patients with elevated defibrillation thresholds.
    Brooks R; Torchiana D; Vlahakes GJ; Ruskin JN; McGovern BA; Garan H
    J Am Coll Cardiol; 1993 Aug; 22(2):569-74. PubMed ID: 8335831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the ventricular electrogram amplitude in sinus rhythm and in ventricular fibrillation.
    Leitch JW; Yee R; Klein GJ; Jones DL; Murdock CJ
    Pacing Clin Electrophysiol; 1990 Sep; 13(9):1105-9. PubMed ID: 1700384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.